

Focus Group Results

Blood stream infections associated with IV catheters and similar are a common cause of death in US hospitals. It is standard of care to utilize medical devices (disposable discs) to prevent such infections, however, the technology is old and sub-optimal.

ATTWILL saw a need to rethink the design of insertion site infection prevention technology based on clinical data and healthcare experience with current designs. This is what we heard from the clinicians:

- The edges of the existing disc stays square and stiff over time. This is believed to cause causing skin irritation and discomfort for the patient **OUR RESPONSE:** Softer less cytotoxic material can make the disc more comfortable, wearable and cause less irritation.
- Existing disc technologies were not designed with component interfacing in mind as part of the total solution including patch (disc), dressing and catheter. **OUR RESPONSE:** HaloGUARD was designed from a solutions perspective to conform better with complementary components.
- The design of the existing disc is believed to cause a potential for catheter kinking – **OUR RESPONSE:** The HaloGUARD uses soft, bevelled edges to help reduce catheter angles under the permanent dressing.
- The current disc has limited antimicrobial load and absorbency. **OUR RESPONSE:** a more absorbant material with 7 days (168 hours) of in-vitro efficacy



The Haloguard device has been designed in order to address a number of clinical concerns yet continue to meet the or surpass the expected characteristics of anti-microbial dressings used in these applications.

The FDA cleared HaloGUARD disc has addressed all of the issues that surfaced in focus group research, including using softer materials, using a bevelled edge to address patient comfort and catheter kinking. Further, the company has completed studies that show superior observational wound healing characteristics, less irritation, improved absorbancy, and lower cytotoxicity scores.

At the same time, Haloguard has all the same functional characteristics as the existing device, so clinicians and facilities do not have to change their practice while adopting a higher standard of insertion site wound dressing.

HaloGUARD™ Protective Disc with CHG (Chlorhexidine Gluconate) has demonstrated in-vitro antimicrobial efficacy against a broad range of organisms known to cause Catheter Related Blood Stream Infections (CRBSI's)



CONTACT:

Integrated Medical Systems, Inc. (IMS)
Customer Service: 800-755-3800
www.integratedmedsys.com